The author holds MAIA and argues the key upside is platform breadth: if the therapy works in lung cancer, it should apply to other solid tumor cancers involving telomere lengthening. That optionality would create many additional opportunities beyond the initial indication if the approach proves out. No specific catalyst date, financial target, or risk is given.